Background: Mitoxantrone (MTX) is an immunosuppressive drug approved for multiple sclerosis (MS) treatment. Objective: The aim of this study is to evaluate and to compare the clinical and neuroradiological responses to MTX in relapsing—remitting (RR) and secondary progressive (SP) MS patients.
Methods: We conducted a retrospective, non-randomized, open-label, observational study to evaluate the clinical and neuroradiological response to the drug in 79 patients with RR MS and 210 patients with SP MS.
Results: A statistically significant reduction (p < 0.001) in the number of relapses was observed during MTX treatment and in the year after in both RR and SP MS patients. On the contrary, an opposite behavior in terms of disease progression was found in RR compared with SP MS patients, resulting in a statistically significant improvement of the Expanded Disability Status Scale score during the MTX treatment (p < 0.001) and in the year after (p < 0.001) for RR MS patients compared with a continuous, although mild, worsening of the disability in SP MS patients (p < 0.001). Finally, a significant reduction (p < 0.001) of new Gd-enhanced lesions in both RR and SP MS patients was observed in a subgroup of 224 individuals who underwent a brain MRI evaluation before and after MTX treatment.
Conclusions: MTX should be considered as an effective therapeutic option in RR MS patients with evidence of relevant disease activity, but the potential life-threatening adverse events and the overall benefit—risk ratio must be carefully evaluated at individual patient level.
Fidler JM, DeJoy SQ, Smith III FR and Gibbons Jr JJSelective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol1986; 136: 2747-2754.
2.
Fidler JM, DeJoy SQ and Gibbons Jr JJSelective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol1986; 137: 727-732.
3.
Levine S. and Saltzman A.Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol1986; 13: 175-181.
4.
Mustafa M., Diener P., Sun JB, Link H. and Olsson T.Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity. Scand J Immunol1993; 38: 499-507.
5.
Morrissey SP, Le Page E. and Edan G.Mitoxantrone in the treatment of multiple sclerosis. Int MS J2005; 12: 74-87.
6.
Lublin FD, Lavasa M., Viti C. and Knobler RLSuppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol1987; 45: 122-128.
7.
Edan G., Miller D., Clanet M., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry1997; 62: 112-118.
8.
Millefiorini E., Gasperini C., Pozzilli C., et al. Randomized placebo-controlled trial of mitoxantrone in relapsing- remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol1997; 244: 153-159.
9.
Hartung HP, Gonsette R., Konig N., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet2002; 360: 2018-2025.
10.
Van de Wyngaert FA, Beguin C., D’Hooghe MB, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg2001; 101: 210-216.
11.
Martinelli Boneschi F., Rovaris M., Capra R. and Comi G.Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev2005; 4: CD002127.
12.
Cohen BA and Mikol DDMitoxantrone treatment of multiple sclerosis: safety considerations. Neurology2004; 63: S28-32.
13.
Ghalie RG, Edan G., Laurent M., et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology2002 ; 59: 909-913.
14.
Neuhaus O., Kieseier BC and Hartung HPMechanisms of mitoxantrone in multiple sclerosis-what is known?J Neurol Sci2004; 223: 25-27.
15.
Lassmann H. , Bruck W. and Lucchinetti CFThe immunopathology of multiple sclerosis: an overview. Brain Pathol2007; 17: 210-218.
16.
McDonald WI , Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50: 121-127.
17.
Polman CH, Reingold SC, Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘‘McDonald Criteria’’. Ann Neurol2005; 58: 840-846.
18.
Kurtzke JFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444-1452.
19.
Avvisati G. , Lo Coco F., Diverio D., et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study. Blood1996; 88: 1390-1398.
20.
Neuhaus O., Kieseier BC and Hartung HPMitoxantrone (Novantrone) in multiple sclerosis: new insights. Expert Rev Neurother2004; 4: 17-26.
21.
Cocco E., Marchi P., Sardu C., et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler2007; 13: 975-980.
22.
Debouverie M., Taillandier L., Pittion-Vouyovitch S., Louis S. and Vespignani H.Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment . Mult Scler2007; 13: 626-631.
23.
Buttinelli C., Clemenzi A., Borriello G., Denaro F., Pozzilli C. and Fieschi C.Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. Eur J Neurol2007; 14: 1281-1287.
24.
Le Page E., Leray E., Taurin G., et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry2008; 79: 52-56.
25.
Goodin DS, Arnason BG, Coyle PK, Frohman EM and Paty DWThe use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology2003; 61: 1332-1338.
26.
Gauthier SA and Weiner HLCyclophosphamide therapy for MS. Int MS J2005; 12: 52-58.
27.
Coles AJ, Cox A., Le Page E., et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol2006; 253: 98-108.
28.
Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis . N Engl J Med2008; 359: 1786-1801.
29.
Paul F., Dorr J., Wurfel J., Vogel HP and Zipp F.Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry2007 ; 78: 198-200.
30.
Ellis R. and Boggild M.Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?Mult Scler2009; 15: 505-508.
31.
Vicari AM, Ciceri F., Folli F., et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia1998; 12: 441-442.
32.
Pascual AM, Tellez N., Bosca I., et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler2009; 15: 1303-1310.
33.
Martinelli V., Bellantonio P. and Bergamaschi R.Incidence of acute leukemia in multiple sclerosis patients treated with mitoxantrone: a multi-centre retrospective Italian study. American Academy of Neurology’s 61st Annual Meeting in Seattle, WA, 25 April- 2 May, 2009.
34.
Verdecchia A. , Micheli A., Colonna M., Moreno V., Izarzugaza MI and Paci E.A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain. Ann Oncol2002; 13: 1128-1139.
35.
Cavalla P., Rovei V., Masera S., et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci2006; 27: 231-239.
36.
Johnson FR, Van Houtven G., Ozdemir S., et al. Multiple sclerosis patients’ benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol2009; 256: 554-562.
37.
Cotte S., von Ahsen N., Kruse N., et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain2009; 132: 2517-2530.
